Steroids for Pediatric Apnea Research in Kids

Obstructive Sleep Apnea Syndrome Clinical Trial

— SPARK  

Official title:

Utility of Nasal Steroids for Treatment of Childhood Obstructive Sleep Apnea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02180672
• Other study ID #: 14-010942
• Secondary ID: R01HL120909
• Status: Completed
• Phase: Phase 3
• Start date: September 2014
• Est. completion date: October 30, 2021

Study information

• Verified date: November 2021
• Source: Children's Hospital of Philadelphia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This double-blind, randomized controlled trial will evaluate the use of nasal corticosteroids for the treatment of the childhood obstructive sleep apnea syndrome (OSAS). Efficacy, duration of action and side-effects will be determined.

Description:

Several studies have suggested that Nasal corticosteroids (NCS) or leukotriene antagonists may be effective in the treatment of childhood OSAS. However, these studies have been limited by factors such as small size, lack of randomization and blinding, short-term follow-up, involvement of children with only very mild OSAS, and/or lack of stratifying for the presence of atopy. Therefore, investigators will plan a randomized controlled trial evaluating the efficacy and safety of NCS vs placebo in children with mild to moderate OSAS. The overall hypothesis is that NCS will be safe and efficacious in the treatment of mild to moderate childhood OSAS, particularly in children with asthma/atopy, but will require ongoing maintenance therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 211
• Est. completion date: October 30, 2021
• Est. primary completion date: December 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 12 Years

Eligibility

Inclusion Criteria

1. 5-10 years of age.

2. Mild to moderate OSAS, defined as an obstructive apnea index of 1-20/hr of total sleep time or obstructive apnea hypopnea index of 2-30/hr of total sleep time.

3. Parent-related symptoms of habitual snoring (>3 nights per week)

4. No history of adenotonsillectomy.

5. Parental/guardian permission (informed consent) and if appropriate, child assent Exclusion Criteria

1. Severe OSAS or significant hypoxemia or hypercapnia on polysomnography, such that definitive treatment should not be delayed (AHI > 30/hr, more than 2% total sleep time with arterial oxygen saturation (SpO2) <90%, end-tidal carbon dioxide partial pressure (PCO2) > 60 mm Hg for > 5 minutes, pathologic arrhythmias).

2. History of recurrent throat infections (as defined by the American Academy of Otolaryngology-Head and Neck Surgery Clinical Practice Guidelines For Tonsillectomy (7)) in the past few years as follows: > 7 episodes in the past year or > 5 episodes/year over the past 2 years or > 3 episodes/year over the past 3 years.

3. Abnormalities on baseline safety screening tests, i.e., Dual Energy X-ray Absorptiometry (DXA) scan showing spine or whole body bone mineral density < -2.0 standard deviations using race specific curves with adjustment for height Z-score; morning cortisol < 3 µg/dl or morning adrenocorticotropic hormone (ACTH) < 10 pg/ml; or ophthalmologic exam demonstrating cataracts (except those with < 2 mm anterior polar cataracts), aphakia or other ocular abnormalities such as glaucoma, retinal coloboma, intraocular inflammation or microphthalmia.

4. Failure to thrive (weight/height < 5th percentile for age and gender), as this may be secondary to OSAS.

5. Severe obesity (BMI z-score > 3) as OSAS is likely to persist in these subjects.

6. Previous adenoidectomy unless adenoidal tissue has been documented to have regrown.

7. Previous tonsillectomy.

8. Continuous positive airway pressure (CPAP) therapy.

9. Any NCS use in the past 3 months or NCS use for > 2 weeks in the past year.

10. Current immunotherapy or daily antihistamine use.

11. Recent (past month) nasal septum ulcers, surgery or trauma.

12. Other major illness other than asthma, such as craniofacial anomalies, endocrine or neuromuscular disease, or past history of cancer. This includes children with conditions that may be worsened by OSAS, such as hypertension or diabetes.

13. Current use of ketoconazole or other potent CYP3A4 inhibitors.

14. Families planning to move out of the area within the year.

15. Subjects who do not speak either English or Spanish well enough to complete the validated neurobehavioral instruments.

16. Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.

Related Conditions & MeSH terms

• Apnea
• Obstructive Sleep Apnea Syndrome
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive

Intervention

Drug:
• Nasal Fluticasone
One spray per nostril, per day.
• Placebo
One spray per nostril, per day.

Locations

Country	Name	City	State
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Children's Hospital of Philadelphia	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Obstructive Apnea Hypopnea Index	Efficacy measure to assess acute response to nasal steroids.; Obstructive apnea hypopnea index (events per hour). Per inclusion/exclusion criteria the expected range for this study at baseline is between 2 and 30 events per hour. Please note that lower and upper ranges can be broader at the 3- and 12-month points.; The obstructive apnea hypopnea index (OAHI) is the sum of obstructive apneas and hypopneas, and mixed apneas divided by the total hours of sleep. Hence, the unit used is events per hour. It ranges from 0 events per hour(meaning no obstructive apneas at all) until 400 events per hour approximately. Higher values indicate more severe obstructive sleep apnea or worse outcome.	3 months
Secondary	OAHI	Efficacy measure to assess duration of response to nasal steroids.; Obstructive apnea hypopnea index (events per hour). Per inclusion/exclusion criteria the expected range for this study at baseline is between 2 and 30 events per hour. Please note that lower and upper ranges can be broader at the 3- and 12-month points.	12 months
Secondary	Nasal Obstruction Symptom Evaluation (NOSE)	Nasal Obstruction Symptom Evaluation (NOSE) scale, a validated scale of nasal obstructive symptoms. The scales ranges from 0-100 with higher values indicating worse nasal obstruction	12 months
Secondary	The Epworth Sleepiness Scale	Epworth Sleepiness scale is a measure of sleepiness that ranges from 0-24, with higher values indicating sleepiness	12 months
Secondary	Pediatric Quality of Life Inventory (PedsQL)	Pediatric Quality of Life Inventory (PedsQL), a well-validated, generic measure of global quality of life, in which scores range from 0 to 100, with higher scores indicating better quality of life	12 month
Secondary	Behavior Rating Inventory of Executive Function (BRIEF)	Behavior Rating Inventory of Executive Function [BRIEF] Global Executive Composite T score, comprising summary measures of behavioral regulation and metacognition [with mean scores of 50 and standard deviation of 10, with higher scores indicating worse functioning]	12 months
Secondary	Conners Abbreviated Symptom Questionnaire	A parent-rated measure of symptoms of attention problems, yielding T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning).	12 months
Secondary	Purdue Peg Board	The Purdue Peg Board is a widely used test of fine motor coordination, yields z-scores with a mean of 0 and a standard deviation of 1, with higher scores indicating better performance.	12 months
Secondary	Conners Continuous Performance Test (CPT)	The CPT is a performance measure of sustained attention that yields T scores with a mean of 50 and a standard deviation of 10 (higher scores indicate worse functioning)	12 months
Secondary	Child Behavior Checklist	The Child Behavior Checklist (CBCL), is a widely used and validated caregiver-completed survey of behavior competencies that yields standardized, age-adjusted scores on internalizing, externalizing and attentional behavior difficulties81, 82. All scores are T scores with a mean of 50 and standard deviation of 10 (higher scores indicate worse functioning).	12-Months

External Links

•   Related Info